Director
AstraZeneca, England, United Kingdom
Ceri Wiggins (PhD) is a Director in the Functional Genomics department at AstraZeneca, leading the Phenotypic Screening group. Her team is responsible for identifying novel targets to support AstraZeneca’s clinical pipeline, by coupling perturbation technologies such as CRISPR with complex cell models to screen at scale. Prior to AZ, Ceri spent 9 years at Horizon Discovery where she lead their R&D team in the development of Horizon’s CRISPR screening platform and internal target discovery initiative. She also led the scientific development and commercialisation of Horizon’s novel base editing platform Pinpoint™.
Disclosure information not submitted.
Monday, February 7, 2022
1:00 PM – 2:30 PM